The FDA wants more safety data on Antares Pharma’s testosterone treatment after noting a case of hives in a clinical trial, presenting a costly delay for the company’s plans to hit the market.

…read more

Source: FDA steps in after a patient on Antares’ ‘low-T’ drug breaks out in hives